

ADULT

DALTEPARIN

This document should be read in conjunction with this **DISCLAIMER**

HIGH RISK Medication 1



RESTRICTED Medication

| Presentation | Syringe: 2500units in 0.2mL | | | | |
|------------------------|---|--|--|--|--|
| | Syringe: 5,000units in 0.2mL | | | | |
| | Syringe: 7,500units in 0.75mL | | | | |
| | Syringe: 10,000units in 1mL | | | | |
| | Syringe: 12500units in 0.5mL | | | | |
| Dose | Refer to relevant KEMH Clinical Guidelines for appropriate dose regimes (links below) | | | | |
| Administration | Subcut Injection | | | | |
| | Inject into the abdomen, while the patient is seated or lying down. Do not expel the air bubble before injecting. Rotate the site of injection. | | | | |
| Pregnancy | 1 st Trimester: Considered safe to use | | | | |
| | 2 nd Trimester: Considered safe to use | | | | |
| | 3 rd Trimester: Considered safe to use | | | | |
| Breastfeeding | Considered safe to use | | | | |
| Monitoring | Platelet count on days 0, 3 and 5, then on alternate days if treatment is continued. | | | | |
| | Antifactor Xa levels in patients at high risk of bleeding (renal impairment, cancer, thin or obese patients, pregnant women) | | | | |
| Clinical | Venous Thrombosis Occurring in the Present Pregnancy | | | | |
| guidelines | Prophylaxis for Women with a Prior Thrombotic Event in Whom No Thrombophilia has been Identified | | | | |
| | VTE Prophylaxis for Women with a Previous Thrombotic Event + with Proven Thrombophilia | | | | |
| Epidural Complications | | | | | |
| | Women with Cardiac Conditions | | | | |
| | | | | | |

| | Thromboprophylaxis after Caesarean Birth | | | | |
|------------|---|--|--|--|--|
| | Risk Assessment and Recommended Venous Thromboembolic Prophylaxis in Patients Admitted for Gynaecological Conditions | | | | |
| | Implementation of the WA Anticoagulation Medication Chart (WAAMC) | | | | |
| | Anticoagulation Medication Chart MR 810.11 | | | | |
| References | Australian Medicines Handbook. Dalteparin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2017 [cited 2017 July 03]. Available from: https://amhonline.amh.net.au/ Therapeutic Guidelines. Cardiovascular: Prevention of venous thromboembolism. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2017 [cited 2017 July 03]. Available from: https://tgldcdp.tg.org.au The Royal Women's Hospital. Dalteparin. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2016 [cited 2017 July 03]. Available from: https://thewomenspbmg.org.au/ | | | | |
| | Society of Hospital Pharmacists of Australia. Dalteparin. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2017 [cited 2017 July 03]. Available from: http://aidh.hcn.com.au | | | | |

| Keywords: | Dalteparin, Fragmin, VTE, thromboembolism, VTE prophylaxis | | | | | |
|---|--|--|-------------------|------------|--|--|
| Publishing: | | | | | | |
| Document owner: | Chief Pharmacist | | | | | |
| Author / Reviewer: | KEMH Pharmacy Department | | | | | |
| Date first issued: | March 2014 | | Version: | 3.0 | | |
| Last reviewed: | March 2017 | | Next review date: | March 2020 | | |
| Endorsed by: | Medicines and Therapeutic Committee | | Date: | Jan 2018 | | |
| Standards Applicable: | NSQHS Standards: | | | | | |
| | 1 Clinical Care is Guided by Current Best Practice | | | | | |
| | 4 Medication Safety | | | | | |
| Printed or personally saved electronic copies of this document are considered uncontrolled. | | | | | | |

© Department of Health Western Australia 2017

Access the current version from the WNHS website.